Mitochondrial Transplantation Therapy Ameliorates Muscular Dystrophy in mdx Mouse Model
Biomolecules · 07.03.2024 · 14 (3) · 316
DOI: 10.3390/biom14030316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 07.03.2024. Verfasst von Mikhail V Dubinin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Cell Biology and Microbiology, Mari State University, pl. Lenina 1, 424001 Yoshkar-Ola, Russia. Hauptthemen laut MEDLINE: Dystrophin, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Duchenne muscular dystrophy is caused by loss of the dystrophin protein. This pathology is accompanied by mitochondrial dysfunction contributing to muscle fiber instability. It is known that mitochondria-targeted in vivo therapy mitigates pathology and improves the quality of life of model animals. In the present work, we applied mitochondrial transplantation therapy (MTT) to correct the pathology in dystrophin-deficient mdx mice. Intramuscular injections of allogeneic mitochondria obtained from healthy animals into the hind limbs of mdx mice alleviated skeletal muscle injury, reduced calcium deposits in muscles and serum creatine kinase levels, and improved the grip strength of the hind limbs and motor activity of recipient mdx mice. We noted normalization of the mitochondrial ultrastructure and sarcoplasmic reticulum/mitochondria interactions in mdx muscles. At the same time, we revealed a decrease in the efficiency of oxidative phosphorylation in the skeletal muscle mitochondria of recipient mdx mice accompanied by a reduction in lipid peroxidation products (MDA products) and reduced calcium overloading. We found no effect of MTT on the expression of mitochondrial signature genes (Drp1, Mfn2, Ppargc1a, Pink1, Parkin) and on the level of mtDNA. Our results show that systemic MTT mitigates the development of destructive processes in the quadriceps muscle of mdx mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Cell Biology and Microbiology, Mari State University, pl. Lenina 1, 424001 Yoshkar-Ola, Russia.
- Prokhorov General Physics Institute, Russian Academy of Sciences, Vavilov St. 38, 119991 Moscow, Russia.
- Laboratory of Mitochondrial Transport, Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Institutskaya 3, 142290 Pushchino, Russia.
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.
ORCID-Profile: Mikhail V Dubinin, Alena A Semenova, Igor I Kireev, Konstantin N Belosludtsev
Förderung
- Russian Science Foundation
Zitieren
APA
Dubinin, M. V., Mikheeva, I. B., Stepanova, A. E., Igoshkina, A. D., Cherepanova, A. A., Semenova, A. A., Sharapov, V. A., Kireev, I. I., & Belosludtsev, K. N. (2024). Mitochondrial Transplantation Therapy Ameliorates Muscular Dystrophy in mdx Mouse Model. Biomolecules, 14(3), 316. https://doi.org/10.3390/biom14030316
Vancouver
Dubinin MV, Mikheeva IB, Stepanova AE, Igoshkina AD, Cherepanova AA, Semenova AA, et al. Mitochondrial Transplantation Therapy Ameliorates Muscular Dystrophy in mdx Mouse Model. Biomolecules. 2024;14(3):316. doi:10.3390/biom14030316
BibTeX
@article{Dubinin2024,
author = {Dubinin, Mikhail V and Mikheeva, Irina B and Stepanova, Anastasia E and Igoshkina, Anastasia D and Cherepanova, Alena A and Semenova, Alena A and Sharapov, Vyacheslav A and Kireev, Igor I and Belosludtsev, Konstantin N},
title = {Mitochondrial Transplantation Therapy Ameliorates Muscular Dystrophy in mdx Mouse Model},
journal = {Biomolecules},
year = {2024},
volume = {14},
number = {3},
pages = {316},
doi = {10.3390/biom14030316}
}
EUVIMED